Because higher rates of axillary adenopathy have been reported with administration of the mRNA (Pfizer-BioNTech and Moderna), the Society of Breast Imaging is recommending that if possible, and when it does not unduly delay care, consider scheduling screening exams prior to the first dose of a COVID-19 vaccination or 4-6 weeks following the second dose of a COVID-19 vaccination. In addition, the organization is also recommending that providers ask patients about COVID-19 vaccine status.
This guidance is only for women who have no breast symptoms getting a screening mammogram. Diagnostic mammograms should not be delayed.
These recommendations are new and while the medical community is still reaching consensus: Health care providers should find out their organization’s recommendations on this issue. Patients should be encouraged to talk to providers before delaying their screening mammogram.
Source
Society of Breast Imaging - Patient Handout
New: March 9, 2024
